Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CodaLytic in metastatic or inoperable breast cancer
NCT05600582Phase 1Withdrawn
- Sponsor
- Codagenix
- Start
- Jan 2023
- Primary completion
- Sep 2024
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of codalytic in breast cancer (4 arms), sponsored by Codagenix. Primary endpoints: Serious Adverse Events (SAEs) at 3 months, Adverse Events (AEs) at 3 months and 1 more. Planned start Jan 2023; status: withdrawn.
02
Drugs
codalytic
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05600582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05600582.